‹ rbtfl

Three Chinese firms debut in Hong Kong on the same day as the HKEX IPO revival rolls on

Chip-interconnect maker Crealights, Alebund Pharma and InsurTech Baige list June 29 in a market that is reclaiming the global IPO crown

Startups·Money· active Whose Money·The Quiet Shift ·8 takes ·
post

developments

  1. First-day close: Crealights +44.7% to HK$165, Alebund Pharmaceuticals +104% (doubling on debut), Baige Online Digital +369% to HK$73 from HK$15.60 issue price; all three rose on the day, confirming strong institutional demand for the HKEX revival's latest cohort. ↗

The split

The same story, as told by newsrooms in different countries. Their words, attributed and linked.

Hong Kong

The Standard

“Three Chinese firms kicked off Hong Kong listings in a wave raising up to $3 billion, a sign the HKEX pipeline has reopened for mainland issuers.”

Hong Kong financial dailyread the original ↗

China

CKGSB Knowledge

“Hong Kong's IPO revival and dual listings are drawing mainland champions offshore, reopening China's window to global capital.”

mainland business-school analysisread the original ↗

United States

IPOX

“Crealights raised ~$195m, Alebund ~$164m and Baige ~$66m on June 29, with Anker pricing, as HKEX led 2026 global IPO volume.”

global IPO-tracking deskread the original ↗

post

Summary

Three China-domiciled companies listed in Hong Kong on June 29: Crealights Technology (chip and optoelectronic interconnects, $195m raised, $1.3b market cap), Alebund Pharmaceuticals ($164m), and InsurTech Baige Online Digital ($66m, priced at the bottom of its range). The cluster of debuts sits inside a bookbuilding wave that local press valued at up to $3b, and a broader HKEX revival that has put Hong Kong back atop global IPO issuance in 2026. Anker Innovations also priced its H-share offering the same day ahead of a July 2 listing. The pattern is mainland firms, some already A-share listed, raising offshore in Hong Kong rather than New York.

The split

This was an Asia-led markets story. Hong Kong's The Standard framed it as proof the HKEX pipeline has reopened at scale; mainland analysis at CKGSB read it as China's champions using Hong Kong as a window to global capital amid friction over US listings. Global trackers like IPOX slotted the day into HKEX's 2026 lead over New York and London. The angle Western IPO coverage tends to miss: these are not US-bound tech names but mainland issuers, chip-interconnect, pharma, insurance, choosing the Hong Kong door, a quiet rerouting of where Chinese growth capital is priced.

By the numbers

  • 3, China-domiciled firms listing in Hong Kong on June 29.
  • ~$195m / ~$164m / ~$66m, raised by Crealights, Alebund and Baige.
  • ~$3b, size of the broader bookbuilding wave per local press.
  • ~$591m, Anker's planned H-share raise, priced June 29 for a July 2 debut.

Why it matters

Where Chinese firms list shows where capital and price discovery are migrating. A multi-debut day plus a deep pipeline marks Hong Kong reclaiming the IPO crown from New York, channeling mainland growth, chips, pharma, fintech, through a market inside China's perimeter and away from US oversight.

What to watch

  • First-day trading performance of the three debuts.
  • Anker's July 2 listing and pricing.
  • Whether more A-share champions add Hong Kong dual listings.
  • HKEX's full-year issuance versus New York and London.

The briefing, by email